SAN DIEGO, Feb. 10, 2020 /PRNewswire/ -- Biocept,
Inc. (Nasdaq: BIOC), a leading commercial provider of liquid
biopsy tests designed to provide physicians with clinically
actionable information to improve the outcomes of patients
diagnosed with cancer, announces that it has entered into an
agreement with a California-based
independent physician association (IPA) to provide its liquid
biopsy testing services to physicians and patients in their
network. Biocept's Target Selector™ offering includes the
choice of individual biomarker tests or a larger liquid biopsy
panel, enabling physicians to select the best approach for each
patient.
"We are very pleased to become a provider for this
well-respected IPA, which offers comprehensive and cutting-edge
medical care to its member physicians and their patients," said
Michael Nall, Biocept's President
and CEO. "Now, more people in California will have access to our Target
Selector™ liquid biopsy testing services, which can help physicians
identify actionable biomarkers in patients diagnosed with cancer
and design personalized treatment programs in order to improve
outcomes. We expect to announce agreements with other
value-based healthcare delivery systems as the year
progresses."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the
platform has demonstrated the ability to identify cancer mutations
and alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to the expansion in the number of
patients that will have an opportunity to benefit from our liquid
biopsy testing platforms, our ability to improve the outcomes
of patients diagnosed with cancer, and the potential clinical
utility of our proprietary technology platform, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Investors:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
Media:
CORE IR
Jules
Abraham
julesa@coreir.com
917-885-7378
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-enters-into-laboratory-services-agreement-with-california-based-independent-physician-association-301001199.html
SOURCE Biocept, Inc.